What's new? Log in Free sign up

PAVmed (PAVM) News and press releases

Company Profile

News

From Benzinga Pro

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Cantor Fitzgerald Downgrades PAVmed to Neutral, Lowers Price Target to $1.5

News, Downgrades, Price Target, Analyst Ratings

Cantor Fitzgerald analyst Ross Osborn downgrades PAVmed (NASDAQ:PAVM) from Overweight to Neutral and lowers the price target from $4 to $1.5.

S&P 500 Down Over 1%; Bit Brother Shares Plummet

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping more than 1% on Wednesday.

Why PAVmed Shares Are Falling Today

Penny Stocks, Movers, Trading Ideas

PAVmed Inc. (NASDAQ: PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures.

Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+ program members.

12 Health Care Stocks Moving In Wednesday's Intraday Session

US Stocks Turn Lower; Dow Dips Over 300 Points

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 300 points on Wednesday.

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $1.5

News, Price Target, Analyst Ratings

Lake Street analyst Frank Takkinen maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $5 to $1.5.

PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs

News, Penny Stocks, Health Care, Movers, Trading Ideas, General

12 Health Care Stocks Moving In Tuesday's After-Market Session

PAVmed And Lucid Diagnostics To Provide Strategic Business Update

PAVmed Inc. (NASDAQ:PAVM, PAVMZ)), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 325 companies set new 52-week lows.

PAVmed Partners With Novosound On Ultrasound Imaging Technology

Biotech, News, General

License option and joint R&D agreement seek to apply Novosound's groundbreaking flexible thin-film ultrasound technology to intravascular imaging PAVmed Inc. (NASDAQ:PAVM, PAVMZ)))) ("PAVmed"), a

Stocks That Hit 52-Week Lows On Friday

During Friday's trading, 293 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 241 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 89 companies set new 52-week lows.

12 Health Care Stocks Moving In Thursday's After-Market Session

PAVmed Q3 EPS $(0.15) Beats $(0.26) Estimate, Sales $76.00K Miss $230.00K Estimate

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.26) by 42.31 percent. This is a 50 percent decrease over losses of $(0.10) per share from the same

Earnings Scheduled For November 15, 2022

Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.

Lucid Diagnostics Commences Production Of EsoCheck Devices With High-Volume Manufacturer

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed

Press releases

From Benzinga Pro

PAVmed and Lucid Diagnostics Provide Strategic Business Update

Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercialization efforts Conference call to be held today at 4:30PM

PAVmed Partners with Novosound on Ultrasound Imaging Technology

License option and joint R&D agreement seek to apply Novosound's groundbreaking flexible thin-film ultrasound technology to intravascular imaging PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), a diversified

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

Executes first commercial contract with leading New Jersey oncology practice PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device,

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

EsoCheck esophageal cell sampling procedure performed on 687 patients with 98% success rate Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), a commercial-stage, cancer prevention medical diagnostics company, and

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

EsoGuard test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch Conference call and webcast to be held today at 4:30 PM EDT PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) (the "Company"

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

EsoGuard test volume increased 28% sequentially and 436% annually Conference call and webcast to be held today at 4:30 PM EDT Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer

PAVmed to Participate in BTIG Digital Health Forum

PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed", the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that

Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today